REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.

Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The beginning of ...

CRL introduced TURBOFLEX, a glass railing system. TURBOFLEX enables glaziers to save time during the railing installation process while achieving adjustability and performance. The new railing system ...

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...

Although no safety or manufacturing concerns were identified, the agency raised questions regarding the reliability of clinical findings due to inconsistent trial results. The Food and Drug ...